首页> 美国卫生研究院文献>Cancer Management and Research >LAPTM4B facilitates tumor growth and induces autophagy in hepatocellular carcinoma
【2h】

LAPTM4B facilitates tumor growth and induces autophagy in hepatocellular carcinoma

机译:LAPTM4B促进肝癌的生长并诱导自噬

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Hepatocellular carcinoma (HCC) is one of the most frequent cancers and the third leading cause of cancer-related deaths. It has been reported that lysosomal associated transmembrane protein LAPTM4B expression is significantly upregulated in human cancers and closely associated with tumor initiation and progression.>Purpose: We aimed to reveal the relevance of LAPTM4B and the pathogenesis of HCC. Methods: Cell viability assessment, colony formation assay, in vivo xenograrft model, microarray, real-time PCR, immunofluorescence and western blot analysis were applied.>Results: Our results demonstrated that LAPTM4B promoted HCC cell proliferation in vitro and tumorigenesis in vivo. Additionally, upon starvation conditions, LAPTM4B facilitated cell survival, inhibited apoptosis and induced autophagic flux. Expression profiling coupled with gene ontology (GO) analysis revealed that 159 gene downregulated by LAPTM4B silencing was significantly enriched in response to nutrient and some metabolic processes. Moreover, LAPTM4B activated ATG3 transcription to modulate HCC cell apoptosis and autophagy.>Conclusion: Our findings demonstrate that LAPTM4B acts as an oncogene that promotes HCC tumorigenesis and autophagy, and indicate that LAPTM4B may be used as a novel therapeutic target for HCC treatment.
机译:>背景:肝细胞癌(HCC)是最常见的癌症之一,也是与癌症相关的死亡的第三大诱因。据报道,溶酶体相关的跨膜蛋白LAPTM4B的表达在人类癌症中显着上调,并与肿瘤的发生和发展密切相关。方法:应用细胞活力评估,集落形成测定,体内异种移植模型,微阵列,实时PCR,免疫荧光和蛋白质印迹分析。>结果:我们的结果表明,LAPTM4B促进了HCC细胞的体外增殖和体内肿瘤发生。另外,在饥饿条件下,LAPTM4B促进细胞存活,抑制细胞凋亡并诱导自噬。表达谱分析和基因本体论(GO)分析显示,通过LAPTM4B沉默而下调的159个基因在营养和某些代谢过程中显着丰富。此外,LAPTM4B激活ATG3转录以调节HCC细胞凋亡和自噬。>结论:我们的研究结果表明LAPTM4B充当促进HCC肿瘤发生和自噬的致癌基因,并表明LAPTM4B可用作新型治疗剂HCC治疗的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号